Company intelligence / Profile preview
Shanghai Longwood Biopharmaceuticals Co., Ltd.
Shanghai, Shanghai, Chinalwbpsh.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
The company has several products in clinical trials, with two in Phase 2. Their JAK1 selective inhibitor LW402 has shown promising results in Phase 2 trials for rheumatoid arthritis and has completed enrollment for atopic dermatitis trials. Another compound, LW231, is being evaluated for chronic hepatitis B virus infection[1][2][6][9].
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Shanghai Longwood Biopharmaceuticals Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Longwood Biopharmaceuticals Co., Ltd..